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Many proteins are being found to bind inositol
phosphates with varying degrees of specificity; the
variety of domains that can bind inositol phosphates
suggests convergent evolution, but the functions of
most of the binding sites are not yet clear.
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Perhaps we should not be surprised if, as more and more
intracellular inositol phosphates and lipids are discovered,
the number of proteins found to bind them also grows.
But as the number of inositol phosphate-binding proteins
increases, one might hope that some pattern would
emerge in the form of some similarity in sequence or func-
tion of the inositol phosphate-binding proteins. So far,
however, the contrary seems to be the case. Convergent
evolution appears to have operated in such a way that
almost any protein domain can bind an inositol phosphate
if required.
PH domains
The best example of the specialized use of a general
domain to bind inositol phosphates may be the pleckstrin
homology (PH) domain of phospholipase C d1 (PLCd1).
PH domains vary considerably in sequence, and presum-
ably therefore in function [1]. Like many other PH
domains [2], that of PLCd1 can bind the enzyme’s sub-
strate, phosphatidylinositol 4,5-bisphosphate (PIP2), but it
is unlikely to be part of the active site of PLCd1, as the
enzyme functions as a PLC, albeit with different kinetics,
without its PH domain (see [2] for references). Although all
PLCs have such PH domains, that of PLCd1 is unusual in
that it binds the enzyme’s product, inositol 1,4,5-triphos-
phate (IP3), with a high affinity. IP3 binding inhibits the
enzyme’s activity, providing regulation by product inhibi-
tion and so preventing uncontrolled activation — likely to
be particularly useful given that, as far as we know, PLCds
are regulated only by Ca2+, and not directly by receptors.
This probable biological significance of IP3 binding is sup-
ported by its remarkable isomeric specificity (see [2]), and
we now have a beautiful three-dimensional structure of the
PLCd1 PH domain to explain how this specific binding is
mediated [2]. It appears that several discrete residues —
mostly positively charged, as one might expect — in the
first three b sheets of the PH domain contribute to the for-
mation of a highly specific IP3-binding site (Fig. 1). As
these residues are different from their equivalents in other
PH domains, we can understand why most PH domains do
not bind IP3. We use the word ‘most’ instead of ‘all’ in the
preceding sentence because the PH domains of several
other proteins — dynamin, spectrin and pleckstrin, for
example — do bind IP3, but the binding is very much
weaker. Ferguson et al. [2] discuss this, and show how the
unique structure of the PLCd1 PH domain accounts for
the much higher affinity by having more residues that can
interact directly with IP3.
So IP3 binding is probably a specific function for this par-
ticular PH domain. It will be interesting to see three-
dimensional structures showing how this and other PH
domains bind PIP2, as this may help us to evaluate how
many such PIP2-binding sites are physiologically relevant.
The problem with investigating the binding of a lipid sus-
pension (with or without detergent) to a protein in
aqueous solution is that an otherwise very weak interaction
of the lipid headgroup with any domain (such as a PH
Figure 1
A ribbon diagram of PH domain of PLCd with bound IP3 [2]. (Graphic
courtesy of Mark Lemmon.)
domain) can be distorted in the binding assay to an appar-
ently strong binding, simply because the presence of
hydrophobic regions in the protein makes the bound lipid
feel happier staying where it is rather than dissociating
back into the very polar environment of the solution. It is
possible that many apparent high-affinity binding sites for
PIP2 in proteins never get to see PIP2 in vivo.
C2 domains
The other clear example of a phospholipid-binding
domain that is ‘adapted’ for inositol phosphate binding is
the ‘C2B domain’, which is found in several proteins. C2
domains were first described as Ca2+-dependent phospho-
lipid-binding domains in protein kinase C, and have been
extensively examined with respect to their properties and
functions in proteins of the synaptotagmin family. The
synaptotagmins have two adjacent C2 domains, C2A and
C2B, and the C2A domain binds phospholipids by a Ca2+-
dependent mechanism, whereas the C2B domain binds
them independently of Ca2+.
The ability of C2 domains to bind inositol phosphates was
discovered by chance by Fukuda et al. [3], who purified
synaptotagmin II as an IP4-binding protein. They showed
that the IP4 was binding to the protein’s C2B domain (IP6
binds with a higher affinity than IP4, so from now on we
shall call this an IP6-binding domain). Moreover, by com-
paring the sequence of the synaptotagmin II C2B domain
with C2B domains of some other proteins that they found
do not bind IP6, Fukuda et al. [3] were able to identify
some lysine residues that are critical for IP6 binding. All
synaptotagmin C2 domains have a lysine/arginine-rich
stretch, and in the C2B domain of synaptotagmin II there
is a remarkable cluster of consecutive lysines that are
clearly responsible for the the IP6 binding. However,
further studies from the same laboratory have shown that
things are not quite that simple.
In their second paper on this topic, Fukuda et al. [4] investi-
gated IP6 binding (again using [3H]-IP4 as the ligand) by
the C2B domains of synaptotagmins III and IV, and they
found that, despite having an identical pattern of lysines
and arginines in the crucial region to synaptotagmin II, the
C2B domain of synaptotagmin III does not bind IP6 at all. It
appears from experiments with hybrid domains that, in the
synaptotagmin III C2B domain, residues on the carboxy-
terminal side of the lysine/arginine-rich region have an
inhibitory influence of some kind on IP6 binding, perhaps
by their effect on the way the C2B domain folds. There is,
however, no immediately obvious (at least to us) difference
in the C2B domain sequences that would explain such an
inhibitory influence. Solving this puzzle may need the
determination of further three-dimensional structures.
Having said that, we believe that we may nevertheless
have gained some possible insight into the nature of this
phenomenon recently. We purified (from platelets) and
cloned the gene for a putative IP4 receptor, a highly-spe-
cific (1,3,4,5)IP4-binding protein which also has two C2
domains similar to those in the synaptotagmins [5]; the
protein is a member of the GAP1 family so we call it
GAP1IP4BP. This protein’s affinity for inositol phosphates
is very different from that of synaptotagmin II, in that it is
extraordinarily specific for (1,3,4,5)IP4 (IP6, for example,
binds more than two orders of magnitude more weakly
than does IP4). The work of Fukuda et al. [3], however, sug-
gested to us that the lysine/arginine-rich stretch of the C2B
domain of GAP1IP4BP is again the likely IP4-binding site.
We have confirmed the likelihood of this suggestion
recently, by finding that a 25-residue peptide from the C2B
domain of GAP1IP4BP, containing the highly basic sequence
KKTKVKKK, binds IP4 with an affinity and specificity not
far removed from that of the native protein (unpublished
data). Why we bring this up as relevant here is that such a
peptide is unlikely to have extensive tertiary structure, and
indeed, in the only C2 domain of known three-dimensional
structure — the C2A domain of synaptotagmin I — the
lysine-rich stretch is unstructured [6]. We believe, there-
fore, that binding of IP4 to a C2 domain may involve an
‘induced fit’ — that is, the unstructured polypeptide chain
may coil around to form a basket-like structure, allowing
the lysines or arginines to interact with the phosphates of
the IP4. We have made a space-filling model of the
KKTKVKKK peptide, and find that it can indeed coil to
form a remarkably specific IP4-binding structure.
If the C2B domains of synaptotagmins II and IV bind IP6
in a similar way, this could explain the observation that
proteins with very similar sequences — such as synapto-
tagmin III and synaptotagmin II — have very different
IP6-binding properties. Thus, a small difference in
sequence might affect the domain structure in such a way
as to prevent, by steric hindrance, the polypeptide chain
from coiling around the inositol phosphate ligand, and this
would very greatly reduce the protein’s binding affinity. If
true, then this would be very different from the way in
which the PH domain of PLCd1 binds IP3, and it will be
fascinating to find out whether other proteins that bind
IP6 use a similar mechanism.
Other IP6-binding proteins
We now know quite a large handful of other IP6-binding
proteins (for references, see [7]). The first clear identifica-
tion of such a protein was by Ann Theibert and colleagues,
who showed that an IP4/IP6-binding protein — again
favouring IP6 — purified from brain is AP-2, one of the
clathrin assembly proteins. Another protein involved in
clathrin assembly, AP-3, was recently shown to bind IP6.
Moreover, coatomer, another protein complex involved in
vesicle assembly and movement, but in this instance in the
Golgi apparatus and endoplasmic reticulum, also binds IP6.
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Here, at least, some functional pattern is suggested. In
each of these examples, IP6 has been shown to inhibit the
relevant protein function in vitro; it has also been shown to
inhibit exocytosis of synaptic vesicles [8], in which synap-
totagmin II is involved, but whether this pharmacological
phenomenon reflects a physiological control mechanism
remains unproven. 
We also don’t know whether IP6 actually modulates the
structures of the proteins to which it binds allosterically —
perhaps by an induced-fit, as discussed — or whether it
merely changes the charge distribution on interacting
domains. In these other IP6-binding proteins, the IP6
binding sites have not yet been identified, though they all
contain lysine/arginine-rich regions. Most of the groups
studying these interactions have noted a couple of prob-
lems for possible physiological functions of IP6 binding:
first, the affinities observed suggest that, unless there is
marked compartmentalization of IP6 in the cell or some
other factor modulates the binding, all these binding sites
will be permanently saturated with IP6; and second, IP6
levels do not change very much or at all rapidly in intact
cells, as far as we know.
The three most obvious possible resolutions to this
conundrum are as follows. First, that these binding sites
actually recognize something else in vivo, phospholipids
such as PIP2 or PIP3, for example (of course, this is not to
say that IP6 could not compete for, and therefore modu-
late, the lipid binding). Second, bound IP6 may act as
some kind of ‘bridge’ between proteins: this may be true,
for example, in the case of clathrin AP-2 and the C2B
domain of synaptotagmin I [9], which interact tightly and
both of which bind IP6 [3] — the analogy of oil between
the cogs of a gear system is not entirely inappropriate.
Third, as suggested recently by Vogelmeier et al. [10],
phosphorylation of IP6 may act as an energy source for
vesicle fusion/secretion.
The presence in cells of pyrophosphate (PP)-containing
inositol phosphates — IP5-(PP) and IP4-(PP)2, more
loosely termed IP7 and IP8, respectively — has puzzled all
those working in the inositol phosphate field ever since
they were discovered. Their interaction with IP6-binding
sites has, where studied, been found to be as tight or
tighter than IP6 (see [7] for references), and metabolic
studies reveal that they are turning over much more
quickly than IP6 (see [7]). Vogelmeier et al. [10] recently
purified an IP6 kinase and found that it would effectively
transfer phosphate from IP7 back to ADP to make ATP,
so they suggested that the pyrophosphate-containing
inositol phosphates may be acting as a localized energy
source — a role akin to that of creatine phosphate in
muscle, though creatine phosphate is not tightly localized
within the cell. We wonder if the involvement is even
more direct: if the pyrophosphate-containing inositol
phosphates were actually bound to one or more proteins
involved in the membrane fusion events, then hydrolysis
of the high energy pyrophosphate bond may provide the
driving force for the fusion.
Other inositol phosphate-binding proteins
Other inositol phosphate-binding proteins form another
large group. Kanematsu et al. [11], for example, have
described what appears to be an (1,4,5,6)IP4-binding
protein in brain, and there must be an (3,4,5,6)IP4-binding
protein in some cells to explain the specific physiological
effects of this compound [12]. Theibert et al. [13] have
found at least two unidentified proteins in brain that bind
IP4 with an impressive specificity, and Reiser et al. [14]
have found another. Aldolase is yet another protein whose
inositol phosphate-binding properties are known but still
of unproven significance [15]. Very recently, vinculin has
also been identified as an IP6-binding protein by
O’Rourke et al. [16]. Moreover, there are at least two
highly specific IP3-binding proteins to be included — the
receptor and 3-kinase for this molecule — which bear no
sequence homology either to each other, or to the PH
domain of PLCd1. We start to get the impression of con-
vergent evolution run amok!
Finally let us not forget the grand-daddy of them all,
haemoglobin. In erythrocytes from some species — such
as birds and turtles — this protein is allosterically modu-
lated by IP4 and IP5 (for references see [17]). This is not
so in the embryos of these species, in which 2,3-bisphos-
phoglycerate fulfills this function (as it does in our red
cells), but just before hatching a switch occurs to give a
major physiological function to these inositol polyphos-
phates. Perhaps this is the system we should study to help
us understand why evolution has done this kind of thing
so often.
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